SARS-CoV-2 Spike RBD Products
Given the critical role of the spike protein RBD in the interaction with the ACE2 receptor and viral entry, a number of neutralizing antibodies against the RBD have been developed as potential therapeutics for treating COVID-19 (3). These antibodies bind the RBD domain on the S1 subunit inhibiting the interaction with ACE2 (3). However, more studies need to be done as neutralizing antibodies can result in antibody-dependent enhancement, in which the viral entry and replication within the host cell is increased (4). One potential way to combat antibody-dependent enhancement is the use of nanobodies (4). Furthermore, there are currently several vaccine strategies that are in clinical trials, or recently federally approved, that utilize the spike protein in different forms (e.g. full length, S1 RBD, RBD-Fc, N-terminal) for protecting against SARS-CoV-2 infection (4,5). These vaccine strategies include DNA vaccines, viral vector-based vaccines, RNA vaccines, and subunit vaccines (4,5).
References
1. Pillay T. S. (2020). Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. Journal of Clinical Pathology. https://doi.org/10.1136/jclinpath-2020-206658
2. Malik Y. A. (2020). Properties of Coronavirus and SARS-CoV-2. The Malaysian Journal of Pathology.
3. Ho M. (2020). Perspectives on the development of neutralizing antibodies against SARS-CoV-2. Antibody Therapeutics. https://doi.org/10.1093/abt/tbaa009
4. Samrat, S. K., Tharappel, A. M., Li, Z., & Li, H. (2020). Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development. Virus Research. https://doi.org/10.1016/j.virusres.2020.198141
5. Sternberg, A., & Naujokat, C. (2020). Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. Life Sciences. https://doi.org/10.1016/j.lfs.2020.118056
20 results for "SARS-CoV-2 Spike RBD" in Products
20 results for "SARS-CoV-2 Spike RBD" in Products
SARS-CoV-2 Spike RBD Products
Given the critical role of the spike protein RBD in the interaction with the ACE2 receptor and viral entry, a number of neutralizing antibodies against the RBD have been developed as potential therapeutics for treating COVID-19 (3). These antibodies bind the RBD domain on the S1 subunit inhibiting the interaction with ACE2 (3). However, more studies need to be done as neutralizing antibodies can result in antibody-dependent enhancement, in which the viral entry and replication within the host cell is increased (4). One potential way to combat antibody-dependent enhancement is the use of nanobodies (4). Furthermore, there are currently several vaccine strategies that are in clinical trials, or recently federally approved, that utilize the spike protein in different forms (e.g. full length, S1 RBD, RBD-Fc, N-terminal) for protecting against SARS-CoV-2 infection (4,5). These vaccine strategies include DNA vaccines, viral vector-based vaccines, RNA vaccines, and subunit vaccines (4,5).
References
1. Pillay T. S. (2020). Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. Journal of Clinical Pathology. https://doi.org/10.1136/jclinpath-2020-206658
2. Malik Y. A. (2020). Properties of Coronavirus and SARS-CoV-2. The Malaysian Journal of Pathology.
3. Ho M. (2020). Perspectives on the development of neutralizing antibodies against SARS-CoV-2. Antibody Therapeutics. https://doi.org/10.1093/abt/tbaa009
4. Samrat, S. K., Tharappel, A. M., Li, Z., & Li, H. (2020). Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development. Virus Research. https://doi.org/10.1016/j.virusres.2020.198141
5. Sternberg, A., & Naujokat, C. (2020). Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. Life Sciences. https://doi.org/10.1016/j.lfs.2020.118056
Reactivity: | SARS-CoV-2 |
Details: | Human IgG Monoclonal Clone #B003Y |
Applications: | WB, ELISA, B/N |
Reactivity: | SARS-CoV-2 |
Details: | Human IgG Monoclonal Clone #B001N |
Applications: | WB, ELISA, B/N |
Reactivity: | SARS-CoV-2 |
Details: | Human IgG Monoclonal Clone #B003N |
Applications: | WB, ELISA, B/N |
Reactivity: | SARS-CoV-2 |
Details: | Human IgG Monoclonal Clone #B001Y |
Applications: | WB, ELISA, B/N |
Recombinant Monoclonal Antibody
Reactivity: | SARS-CoV-2 |
Details: | Llama Monoclonal Clone #RBD-2B9 |
Applications: | ELISA |
Recombinant Monoclonal Antibody
Reactivity: | SARS-CoV-2 |
Details: | Rabbit IgG Monoclonal Clone #HL1866 |
Applications: | ELISA, ICC/IF, Inhibition Activity |
Recombinant Monoclonal Antibody
Reactivity: | SARS-CoV-2 |
Details: | Rabbit IgG Monoclonal Clone #HL1867 |
Applications: | ELISA, ICC/IF, Inhibition Activity |
Recombinant Monoclonal Antibody
Reactivity: | SARS-CoV-2 |
Details: | Human IgG1 Monoclonal Clone #2165 |
Applications: | IHC, ELISA, B/N |
Applications: | ELISA |
Recombinant Monoclonal Antibody
Reactivity: | SARS-CoV-2 |
Details: | Human IgG1 Monoclonal Clone #RBD5324 |
Applications: | ELISA, LFA |
Recombinant Monoclonal Antibody
Reactivity: | SARS-CoV-2 |
Details: | Llama Monoclonal Clone #T3P1-C8 |
Applications: | ELISA |
Recombinant Monoclonal Antibody
Reactivity: | SARS-CoV-2 |
Details: | Llama Monoclonal Clone #T4P5-H12 |
Applications: | ELISA |
Recombinant Monoclonal Antibody
Reactivity: | SARS-CoV-2 |
Details: | Llama Monoclonal Clone #T4P3-B5 |
Applications: | ELISA |
Recombinant Monoclonal Antibody
Reactivity: | SARS-CoV-2 |
Details: | Llama Monoclonal Clone #T4P3-B7 |
Applications: | ELISA |
Recombinant Monoclonal Antibody
Reactivity: | SARS-CoV-2 |
Details: | Llama Monoclonal Clone #T5P7-G10 |
Applications: | ELISA |
Recombinant Monoclonal Antibody
Reactivity: | SARS-CoV-2 |
Details: | Llama Monoclonal Clone #T5P8-F9 |
Applications: | ELISA |
Recombinant Monoclonal Antibody
Reactivity: | SARS-CoV-2 |
Details: | Llama Monoclonal Clone #T5P7-G12 |
Applications: | ELISA |
Recombinant Monoclonal Antibody
Reactivity: | SARS-CoV-2 |
Details: | Llama Monoclonal Clone #T5P4-A12 |
Applications: | ELISA |
Recombinant Monoclonal Antibody
Reactivity: | SARS-CoV-2 |
Details: | Human IgG1 Monoclonal Clone #2355 |
Applications: | ELISA |
Applications: | Binding Activity |